ClinicalTrials.gg
RecruitingNCT07874633Updated Nov 6, 2026

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity

A Phase 3 interventional study of Berobenatide and Placebo in Obesity and Overweight, sponsored by Pfizer. Recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Updated Nov 6, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
432
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing berobenatide in Obesity — 11 open to participants now, 15 under way, 12 of them phase 3. berobenatide · Obesity.

Planned enrollment
8th of 21
432 · median 258
Started
2026
with 14 others
Phase 3
12 of 21
10 open now
Primary completion
2028-06
later than 9 of 14 live
Registered
17th of 21
by date
Lead sponsor
20 of 21
Pfizer

Among the 21 studies testing berobenatide in Obesity, this one is the 8th largest by planned enrollment, is one of 15 that started in 2026, is one of 12 in phase 3, reaches primary completion later than 9 of the 14 other live ones, and was the 17th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

11 of the 21 studies testing berobenatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About berobenatide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing berobenatide in Obesity, or all of them as a file.
02

Study summary

Overweight and obesity are long-term health conditions that can increase the possibility of serious health problems. These problems include heart disease, type 2 diabetes (a condition that causes high blood sugar), and other medical conditions. The purpose of this study is to learn whether berobenatide (PF-08653944) is safe and effective for adults in China who are overweight or obese. Researchers will compare berobenatide with a placebo. A placebo looks like study treatment but does not contain active medicine.

About 432 adults will take part in this study. This study is seeking adults who

  • are obese
  • are overweight with certain weight-related health conditions. Some participants may also have type 2 diabetes. Specific eligibility requirements will be reviewed by the study doctor before enrollment.

Participants will be randomly assigned to receive either berobenatide or placebo. Study treatment will be administered as a shot under the skin. All participants will also receive lifestyle counseling throughout the study.

Researchers will monitor participants throughout the study. They will assess participants' body weight, overall health, and any reactions that may occur. During the study, participants will attend study visits and complete study-related assessments.

Participants may take part in the study for up to approximately 59 weeks. This period includes screening, treatment, and follow-up visits. The information learned from this study may help researchers better understand whether berobenatide could be a treatment option for adults living with overweight or obesity.

03

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Obesity
  • Overweight
  • Weight Management
  • Weight Reduction
  • Body Weight
  • Chronic Weight Management
  • Adults With Obesity
  • Adults With Overweight
  • Metabolic Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 years of age.
  • ≥28 kg/m²; or BMI ≥24 kg/m² and \<28 kg/m² with at least one of the following weight-related co-morbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or T2D.
  • At least one prior unsuccessful dietary weight-loss attempt.

Exclusion criteria

Exclusion Criteria:

  • Significant recent weight change (>5% within 3 months).
  • Type 1 diabetes mellitus.
  • History of pancreatitis.
  • Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple endocrine neoplasia type 2 (MEN2).
  • Recent bariatric surgery or obesity procedures.
  • Pregnancy or breastfeeding.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
432 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive matching placebo by Subcutaneous Injection.

    Other: Placebo

  • Experimental
    Treatment Arm 1

    Participants will receive Berobenatide by Subcutaneous Injection.

    Drug: Berobenatide

  • Experimental
    Treatment Arm 2

    Participants will receive Berobenatide by Subcutaneous Injection.

    Drug: Berobenatide

  • Experimental
    Treatment Arm 3

    Participants will receive Berobenatide by Subcutaneous Injection.

    Drug: Berobenatide

  • Experimental
    Treatment Arm 4

    Participants will receive Berobenatide by Subcutaneous Injection.

    Drug: Berobenatide

Interventions

  • By Subcutaneous Injection

    Also known as: PF-08653944

  • OtherPlacebo

    By Subcutaneous Injection

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in body weight

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Percent change from baseline in body weight in participants without T2D

    Time frame: Baseline, Week 48

  2. Change from baseline in body weight

    Time frame: Baseline, Week 48

  3. Percentage of Participants achieving ≥5% of body weight reduction from baseline

    Time frame: Baseline, Week 48

  4. Percentage of Participants achieving ≥10% of body weight reduction from baseline

    Time frame: Baseline, Week 48

  5. Percentage of Participants achieving ≥15% of body weight reduction from baseline

    Time frame: Baseline, Week 48

  6. Percentage of Participants achieving ≥20% of body weight reduction from baseline

    Time frame: Baseline, Week 48

  7. Change from baseline in waist circumference

    Time frame: Baseline, Week 48

  8. Change from baseline in Fasting triglycerides

    Time frame: Baseline, Week 48

  9. Change from baseline in Non-high-density lipoprotein-cholesterol

    Time frame: Baseline, Week 48

  10. Change from baseline in Systolic Blood Pressure (SBP)

    Time frame: Baseline, Week 48

  11. Change from baseline in Short-Form 36 health survey (SF-36) Physical Function domain score

    Time frame: Baseline, Week 48

  12. Change from baseline in Impact of Weight on Quality of Life-Lite-Clinical Trial (IWQoL-Lite-CT) Physical Function composite score

    Time frame: Baseline, Week 48

  13. Change from Baseline in Body mass index (BMI)

    Time frame: Baseline, Week 48

  14. Change from baseline in Diastolic Blood Pressure (DBP)

    Time frame: Baseline, Week 48

  15. Change from baseline in Total Cholesterol

    Time frame: Baseline, Week 48

  16. Change from baseline in Low-density lipoprotein cholesterol

    Time frame: Baseline, Week 48

  17. Change from baseline in Very low-density lipoprotein cholesterol

    Time frame: Baseline, Week 48

  18. Change from baseline in High-density lipoprotein cholesterol

    Time frame: Baseline, Week 48

  19. Change from Baseline in HbA1c

    Time frame: Baseline, Week 48

  20. Change from Baseline in Fasting plasma glucose

    Time frame: Baseline, Week 48

  21. Change from Baseline in Fasting insulin

    Time frame: Baseline, Week 48

  22. Change from baseline in High-sensitivity C-reactive protein (hs-CRP)

    Time frame: Baseline, Week 48

  23. Change from baseline in Interleukin (IL)-6

    Time frame: Baseline, Week 48

  24. Change from baseline in IL-1 beta

    Time frame: Baseline, Week 48

  25. Change from Baseline in HbA1c in participants with T2D

    Time frame: Baseline, Week 48

  26. Percentage of participants with T2D at screening achieving HbA1c <7.0%

    Time frame: Baseline, Week 48

  27. Percentage of participants with T2D at screening achieving HbA1c <6.5%

    Time frame: Baseline, Week 48

  28. Percentage of participants with T2D at screening achieving HbA1c <5.7%

    Time frame: Baseline, Week 48

  29. Change from baseline in IWQoL-Lite-CT total score

    Time frame: Baseline, Week 48

  30. Change from baseline in IWQoL-Lite-CT Physical Composite

    Time frame: Baseline, Week 48

  31. Change from baseline in IWQoL-Lite-CT Psychosocial Composite

    Time frame: Baseline, Week 48

  32. Change from baseline in SF-36 domain scales and component summary scales

    Time frame: Baseline, Week 48

  33. Change from baseline in EuroQoL5-Dimension 5-Level (EQ-5D-5L) index score

    Time frame: Baseline, Week 48

  34. Change from baseline in EuroQol Visual Analogue Scale (EQ-VAS)

    Time frame: Baseline, Week 48

  35. Incidence proportion of Treatment-emergent adverse event (TEAE)

    Time frame: Up to Week 55

  36. Incidence proportion of Serious adverse event (SAE)

    Time frame: Up to Week 55

  37. Incidence proportion of Adverse event (AE) leading to permanent discontinuation from study intervention or study

    Time frame: Up to Week 55

  38. Incidence proportion of Adverse events of special interest (AESIs)

    Time frame: Up to Week 55

  39. Incidence proportion of Clinical laboratory abnormalities

    Time frame: Up to Week 55

07

Study locations

1 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jun 2028, 19 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 19 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 15, 2026
StartActual
Oct 28, 2026
Primary completionEst.
Jun 6, 2028
CompletionEst.
Aug 15, 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
4 sites added. 2 sites changed recruiting status (2 now not yet recruiting)
Show 2 sites
  • The Second People's Hospital of Hefei · Hefei, Chinano status→Not yet recruiting
  • Peking University People's Hospital · Beijing, Chinano status→Not yet recruiting
Show 4 added (4 China)
  • Huizhou Central People's Hospital · Huizhou, China
  • The Second Affiliated Hospital of Zhengzhou University · Zhengzhou, China
  • The Second Affiliated Hospital of Nanjing Medical University · Nanjing, China
  • Jiangxi Provincial People's Hospital · Nanchang, China
Nov 6, 2026
Start date
Oct 15, 2026→Oct 28, 2026 (actual)
Nov 6, 2026
Registered
First appeared on the registry
Oct 15, 2026
Show all 2 updates
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    4 sites added. 2 sites changed recruiting status (2 now not yet recruiting)
    Show 2 sites
    • The Second People's Hospital of Hefei · Hefei, Chinano status→Not yet recruiting
    • Peking University People's Hospital · Beijing, Chinano status→Not yet recruiting
    Show 4 added (4 China)
    • Huizhou Central People's Hospital · Huizhou, China
    • The Second Affiliated Hospital of Zhengzhou University · Zhengzhou, China
    • The Second Affiliated Hospital of Nanjing Medical University · Nanjing, China
    • Jiangxi Provincial People's Hospital · Nanchang, China
    Start date Oct 15, 2026→Oct 28, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07874633
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 15, 2026
Start date
Oct 28, 2026
Primary completion
Jun 6, 2028 (estimated)
Completion
Aug 15, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Berobenatide

Start the discussion